Late-Breaking Data from PRESERVE Trial on HOPE Preservation Approach in Heart Transplantation
XVIVO has announced late-breaking preliminary data from the PRESERVE Trial evaluating the hypothermic oxygenated perfusion (HOPE) method for heart preservation using the XVIVO Heart Assist Transport™. The trial successfully met its primary endpoints and focused on the safety and efficacy of HOPE in preserving and transporting extended-criteria donor (ECD) hearts, aiming to improve heart preservation techniques.
TORONTO–(BUSINESS WIRE)–XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservatio